Adequate budgets and transparent management: the challenge to strengthen health in Latin America

29 December 2025

Latin America will need to overhaul how it budgets and finances healthcare if it is to strengthen health systems by 2026 and improve access, quality and efficiency, particularly for patients with chronic and noncommunicable diseases (NCDs), according to a new regional study.

The report, Analysis of health budget practices in eight Latin American countries, was produced by experts from Duke University and funded by the Latin American Federation of the Pharmaceutical Industry (Fifarma). It examines health financing practices in Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico and Peru.

Tough times

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK